About 20% of the worldwide incidence of cancer in humans is attributed to infection by viruses called oncovirus, among them stands out Lymphotropic Virus Human T type 1 (HTLV-1). This virus is associated with several pathologies, among the most studied are paraparesis Tropical Spastic Associated Myelopathy HTLV (HAM / TSP) and the Leukemia Lymphoma, Adult T Cells (ATLL). The HTLV-1 is endemic in many regions of the world, with the highest concentration of cases in southern Japan, while HTLV-2 has been found in greater frequency among intravenous drug users in the United States and Europe, and among native populations of Americas. In Brazil, HTLV 1 is distributed throughout the national territory. The objective of this research was to determine seroprevalence for T-Lymphotropic Virus Human Lymphoproliferative Disease in patients treated at Ophir Loyola Hospital, Belém, Pará The study population consisted of 364 patients diagnosed with lymphoproliferative disease (Hodgkin's lymphoma, Hodgkin lymphoma and non Leukemias Acute and Chronic Lymphoid), treated between January 2005 and December 2011. We used the ELISA test for serological examination and a case was confirmed by PCR. The seroprevalence of HTLV infection in this population was 3.17%, the molecular study of a case showed that it was of HTLV type 1. All serum-reactive individuals were diagnosed as non-Hodgkin lymphoma T cells (p = 0.0021). Among these, the initial manifestation of the disease occurred after the age of 30, the average age was 43.75 years and the majority were women. It is concluded that the prevalence of HTLV in the group studied is consistent with studies of HTLV between leukemias and lymphomas.
|
